Theratechnologies, Inc. – Value Analysis (US OTC:THERF) : December 29, 2017

Capitalcube gives Theratechnologies, Inc. a score of 54.

Our analysis is based on comparing Theratechnologies, Inc. with the following peers – Ono Pharmaceutical Co., Ltd. Unsponsored ADR, Ophthotech Corp., OPKO Health, Inc. and Onconova Therapeutics Inc. (OPHLY-US, OPHT-US, OPK-US and ONTX-US).

Investment Outlook

Theratechnologies, Inc. has a fundamental score of 54 and has a relative valuation of OVERVALUED.

Fundamental Score

Access our research and ratings on Theratechnologies, Inc.

Company Overview

  • Considering peers, relative outperformance over the last year and the last month suggest a leading position.
  • It currently trades at a Price/Book ratio of (10.35).
  • The market expects faster earnings growth from THERF-US than from its peers and also a turnaround in its current ROE.
  • THERF-US has relatively low net profit margins while its asset efficiency is relatively high.
  • Changes in annual revenues are in line with its chosen peers but lags in terms of earnings suggesting that the company is less cost conscious and may be spending for growth.
  • Over the last five years, THERF-US‘s return on assets has declined from about median to less than the median among its peers suggesting that the company’s historical competitiveness in operations is slipping away.
  • Compared with the peers chosen, THERF-US has had faster revenue growth in prior years and a current P/E ratio that suggests faster growth in the future suggesting superior growth expectations.
  • The company is likely overinvesting in a business with only median returns.

Access our research and ratings on Theratechnologies, Inc.

Leverage & Liquidity

  • Of the 4 chosen peers for the company, only 3 of the stocks have an outstanding debt balance. Companies with no debt include ONTX-US.

THERF-US has maintained its Constrained profile from the recent year-end.

  • THERF-US‘s interest coverage is less than (but within one standard deviation of) its five-year average interest coverage of 398.08x.
  • The decrease in its interest coverage to -3.48x from 1.67x (in 2016) was also accompanied by a decrease in its peer median during this period to 497.76x from 500.33x.
  • Interest coverage fell 2.507 points relative to peers. It is also below the 2.50x coverage benchmark unlike the peer median.

Access the detailed analysis for Theratechnologies, Inc.

Key Liquidity Items

Company Debt/Enterprise Value (%) Current Ratio Interest Coverage (x) Cash Flow To Total Debt (%)
Ono Pharmaceutical Co., Ltd. Unsponsored ADR 0.09 3.21 1492.95 6016.54
Ophthotech Corp. 1503.49 12.88 0 65.1
OPKO Health, Inc. 2.06 1.66 -28.52 -40.43
Onconova Therapeutics Inc. 0 0.97 No interest exp 999
Theratechnologies Inc. N/A 1.76 -3.48 -43.02
Peer Median 1.07 1.76 497.76 65.1
Best In Class 0.09 12.88 1492.95 6016.54

Looking for more metrics and analysis for Theratechnologies, Inc.?

Company Profile

Theratechnologies, Inc. is engaged in the development of therapeutic peptide products. It addresses unmet medical needs in metabolic disorders to promote healthy ageing. Its product EGRIFTA reduces excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montreal, Canada.


The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website